Vaxil Bio Ltd.
VXLLF
$0.02
-$0.13-85.27%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 159.90K | 130.30K | 105.80K | 114.90K | 118.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 159.90K | 133.10K | 108.60K | 117.70K | 121.70K |
| Operating Income | -159.90K | -133.10K | -108.60K | -117.70K | -121.70K |
| Income Before Tax | 341.30K | 369.40K | -37.30K | -49.20K | -105.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.34 | 0.37 | -0.04 | -0.05 | -0.11 |
| Earnings from Discontinued Operations | 6.50K | 6.50K | -11.40K | -20.90K | -30.30K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 347.90K | 376.00K | -48.60K | -70.00K | -136.20K |
| EBIT | -159.90K | -133.10K | -108.60K | -117.70K | -121.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.12 | 0.12 | -0.02 | -0.03 | -0.05 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | 0.12 | 0.12 | -0.02 | -0.03 | -0.05 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 12.58M | 11.34M | 10.96M | 10.96M | 10.96M |
| Average Diluted Shares Outstanding | 12.58M | 11.34M | 10.96M | 10.96M | 10.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |